Glycorex notes that a peer-reviewed scientific publication(1) on ABO-incompatible (ABOi) paediatric heart transplantation, conducted last year by Hollis et al. at Great Ormond Street Hospital (GOSH), London, has been selected by the editorial board of the Journal of Heart and Lung Transplantation (JHLT) as one of the journal's top five most impactful papers of 2025.
 
The study retrospectively analysed paediatric heart transplants performed at GOSH between 2013 and 2023 and focuses on children aged 2-9 years undergoing ABO-incompatible heart transplantation. According to the publication, 14 children in this age group received an ABO-incompatible transplant during the study period, with a reported median follow-up time of 4.9 years.
 
Glycosorb® ABO has since 2015 been routinely used to facilitate ABO-incompatible transplantation at GOSH.
 
Dr Richard Issitt, Senior Paediatric Perfusionist, Great Ormond Street Hospital for Children states:
"ABO-incompatible heart transplantation using immunoadsorption has dramatically changed the landscape of paediatric heart transplantation. This study demonstrates the application to a far broader cohort of patients that originally envisioned, meaning more children are waiting less time for a new heart and a chance of a better future." 
 
The authors have been invited to present the study on April 26 this year at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting in Toronto. The publication has also been featured by the JHLT Podcast editors as one of their selected studies of the year.
 
(1) Hollis, Paolo et al. ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?
The Journal of Heart and Lung Transplantation, Volume 44, Issue 12, 1910 - 1917

For more information, please contact:
Johan Nilsson, CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230

Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. 
Product development and production takes place in the company's own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 8,000 transplants in over 30 countries. 
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.